Yutaka Niihara, MD, MPH

Chief Executive Officer, Chairman of the Board

Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, and is the principal inventor of the patented L-glutamine therapy for treatment of sickle cell disease. He is a cofounder of Emmaus, principal investigator for LABioMed at Harbor-UCLA Medical Center and Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA.

His experience includes serving as President, Chief Executive Officer and Medical Director of Hope International Hospice. Board-certified by the American Board of Internal Medicine and the American Board of Internal Medicine/Hematology, Dr. Niihara is licensed to practice medicine in both the U.S. and Japan. His honors include the Lifetime Achievement Award, from the Sickle Cell Disease Foundation of California and the Abigail Kawananako Award. Dr. Niihara received his B.A. in Religion from Loma Linda University, obtained his M.D. from Loma Linda University School of Medicine in 1986, and received his MPH from Harvard School of Public Health in 2006.

Robert Dickey IV, MBA

Director, Chair of the Audit Committee

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Willis C. Lee, MS

Chief Operating Officer, Vice-Chairman of the Board

Mr. Lee has more than 30 years of management and consulting experience with influential companies in the healthcare and semiconductor industries. Prior to joining Emmaus, Mr. Lee led worldwide sales and business development of Yield Dynamics’ product group at MKS Instruments. He joined the Company in 2009 and has served as Chief Operating Officer since May 2011.

He has held various managerial and senior positions at companies including HPL, Syntricity and Reden & Anders, a subsidiary of United Healthcare that provides actuarial services including capitation and risk assessment analyses for healthcare insurance carriers. Mr. Lee received his B.S. and M.S. in Physics from University of Hawaii and University of South Carolina, respectively. He was a member of the American Physical Society, completed TQM/SPC programs, and has published papers in Nuclear Instruments and Methods.

Masaharu Osato, MD

Director

Dr. Osato has been practicing gastroenterology and internal medicine ("GI") at his private practice, the Osato Medical Clinic, Inc. in Torrance, CA since 2001. He completed a GI Fellowship at the Harbor UCLA Medical Center and served as General Internist and Director of Health Screening Center at the Tokyo Adventist Hospital in Japan, as well as at the Kobe Adventist Hospital in Japan. He attended the Loma Linda University School of Medicine in California and completed an internal medicine residency at the Kettering Memorial Medical Center in Dayton, Ohio. Dr. Osato also completed one year of pediatric residency at the Loma Linda University Medical Center.

Wei Peu Zen, MBA

Director

Mr. Zen is Vice Chairman and Chief Executive Officer of Wai Kee Holdings Limited., a Hong Kong-based construction and infrastructure company whose shares are listed on the Main Board of the Hong Kong Stock Exchange Limited. He is also the Chairman of Build King Holdings Limited and Chairman of Road King Infrastructure Limited, both of which are subsidiaries of Wai Kee Holdings Limited. Mr. Zen has over 45 years of experience in civil engineering, and is responsible for the overall management of the Wai Kee Holdings Limited group of companies. He oversees the operations of the group’s construction, quarry and concrete divisions. Mr. Zen holds a B.Sc. degree in Engineering from The University of Hong Kong and a M.B.A. from The Chinese University of Hong Kong and is a member of both the Institution of Civil Engineers and fellow member of the Hong Kong Institution of Engineers and the Institute of Quarrying, UK, respectively. He is a past Honorary Treasurer of the Hong Kong Construction Association and a member of HKTDC Infrastructure Development Advisory Committee. He is also the President of the Hong Kong Contract Bridge Association.

Jane Pine Wood, JD

Director, Chair of the Corporate Governance Committee

Ms. Wood has served since October 3, 2016 as Chief Legal Counsel of BioReference Laboratories, Inc., Elmwood Park, New Jersey, a wholly owned subsidiary of OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company. BioReference Laboratories, Inc. is the nation’s third-largest clinical laboratory with a core genetic testing business and 400-person sales and marketing team. Ms. Wood has over 30 years of experience representing clinical and anatomic laboratories, physicians, imaging centers, home health agencies, mental health providers, hospitals, other healthcare providers, and professional societies in corporate, regulatory, reimbursement, contractual, and other matters. She holds a B.A. degree, summa cum laude, from Texas A&M University and a J.D. degree from Vanderbilt University School of Law and is a member of the State Bars of New Jersey, Massachusetts, Ohio, and Tennessee.

Lori Teranishi

Director

Ms. Teranishi is the founder and Chief Executive Officer of iQ 360, a privately held strategic communications company with offices in Honolulu, San Francisco, New York and Washington DC, whose clients include business leaders, global corporations, innovative startups, nonprofits, and government agencies. She is an expert in business consulting, crisis communications, issues management, corporate positioning, and marketing strategy. She has a successful track record repositioning brands, launching, and executing major change initiatives, counseling companies in the sustainability and ESG (environmental, social, and corporate governance) space and protecting reputations in the face of high-profile litigation, mass company layoffs and regulatory investigations. Before founding iQ 360 in 2010, Ms. Teranishi oversaw product development as a vice president at Visa, where she launched a global loyalty program and other consumer and B2B products. She also served as chief of staff to Visa’s chief operating officer, managing business planning for the company, and prior to that role, had responsibility for variety of communications functions. Ms. Teranishi holds bachelor’s degrees in mass communications and political science from the University of Utah and earned her MBA from the University of San Francisco. Ms. Teranishi was named a Ragan’s Top Woman Leader in Communications in 2020 and received a Distinguished Alumni Award from the University of Utah in 2019.

Alfred Lui, MD

Director, Chair of the Compensation, Nomination Committee

Dr. Lui is an anatomic and clinical pathologist with more than forty years of experience in the active practice of pathology and laboratory medicine. His personal professional corporation dba Innovative Pathology Medical Group was established in 2016. Prior to that time, he was the Laboratory Director for more numerous hospitals and independent clinical laboratories in Southern California and elsewhere. He currently serves as the Laboratory Director for privately-owned HalioDx, Marseille, France and Richmond, Virginia, and Bridge Diagnostics, Irvine, California, and for Lawrence Livermore National Laboratory, Livermore, California. He has founded or co-founded five medical companies and served as the Chairman of the Board, Chief Executive Officer and Laboratory Director of three of the companies. He currently serves as a member of the Board of Directors of two independent laboratory companies. He is a former-President, Board member, and current Education Committee member of the California Society of Pathologists. He is a Fellow of the College of American Pathologists (CAP) where he has served on multiple counsels and committees, including as a former Chair of the Publications Committee. He is a recipient of the CAP’s Distinguished Service award (2013) and the President’s Honors award (2015). He holds a B.A. degree from Andrews University and a M.D. from Loma Linda University. Dr. Lui’s qualifications as a director include his extensive experience as a director and Chief Executive Officer of numerous commercial medical laboratory companies..